Hexahydrocannabinol (HHC)
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol
Overview
Hexahydrocannabinol (HHC) belongs to Cannabinoids.
Effects
- Broadly THC-like: euphoria, relaxation, giddiness, altered perception of time, music and surroundings, and increased appetite. Users often describe it as somewhat milder or more 'functional' than Δ⁹-THC, though this varies with the product and epimer ratio.
- Unwanted effects mirror cannabis: dry mouth, red eyes, increased heart rate, dizziness, impaired coordination and short-term memory, and, especially at high doses, anxiety, paranoia or panic.
- When vaped, effects begin within minutes and last roughly 2–4 hours. Taken orally (edibles) the onset is delayed (30–90 minutes) and effects last considerably longer, as with THC edibles.
Dosing & duration
Most commonly vaped/inhaled (vape pens, e-liquid) or eaten (gummies/edibles). Also smoked as infused flower.. There is no reliable dosing standard for HHC. Commercial products are unregulated mixtures of the more-active (9R) and much-weaker (9S) epimers in undisclosed, variable amounts, so two products labelled the same can differ greatly in strength, and vaped doses in particular cannot be measured meaningfully. The oral figures below are rough PsychonautWiki reference ranges for relatively pure HHC, NOT a recommendation or a 'safe' dose. As with THC edibles, start very low, wait the full delayed onset (up to 1.5–2 hours) before considering more, and do not drive.
Dose ranges
< 5 mg (oral)
5–12 mg (oral)
12–30 mg (oral)
30–60 mg (oral)
60 mg + (oral)
Duration
Vaped: within minutes, oral: 30–90 minutes
Vaped ≈2–4 hours, oral considerably longer (THC-edible-like)
Possible grogginess or 'hangover'. Tolerance with regular use
Chemical & Physical Properties
| Formula | C21H32O2 |
| Molar mass | 316.5 g/mol |
| State | Not reported |
| Melting point | Not reported |
| Boiling point | Not reported |
| Density | Not reported |
| Vapor pressure | Not reported |
| pKa | Not reported |
| LogP | 7.8 (predicted, XLogP3) |
| Solubility | Not reported |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | Not reported |
| CAS (enantiomer) | |
| PubChem CID | 16050328 |
| InChIKey | XKRHRBJLCLXSGE-VNCLPFQGSA-N |
| InChI | InChI=1S/C21H32O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h12-14,16-17,22H,5-11H2,1-4H3/t14?,16-,17-/m1/s1 |
| SMILES | CCCCCC1=CC(=C2[C@@H]3CC(CC[C@H]3C(OC2=C1)(C)C)C)O |
Synonyms
Pharmacodynamics & Biochemistry
HHC (hexahydrocannabinol) is a semi-synthetic cannabinoid: the hydrogenated form of THC, in which the cyclohexene-ring double bond of Δ⁹-THC is saturated. Removing that double bond makes HHC more chemically and thermally stable and more resistant to oxidation than THC, while leaving it pharmacologically THC-like. It is manufactured industrially from hemp-derived CBD (converted to THC, then hydrogenated) and reached the market around 2021–2022 as a 'legal' cannabis alternative. Like THC, HHC is an agonist at the cannabinoid CB1 and CB2 receptors. CB1 activation in the central nervous system produces the psychoactive 'high', euphoria, relaxation, altered perception of time and space, and appetite stimulation, while CB2 is mainly peripheral and immune. Most statements about HHC's effects are extrapolated from THC, because dedicated clinical pharmacology of HHC itself is still very limited. Hydrogenation creates a new stereocentre at C9, so HHC exists as two epimers: (9R)-HHC and (9S)-HHC. The (9R) epimer binds CB1 far more strongly and carries most of the activity, whereas (9S) is much weaker. Commercial HHC is an uncontrolled mixture of the two, so a product's potency depends on its epimer ratio. HHC is highly lipophilic and, like THC, is metabolised in the liver to hydroxylated metabolites and stored in fat, giving a variable and relatively long elimination. The two epimers are metabolised and excreted somewhat differently. Reliable quantitative receptor-affinity data for HHC are not established, so no binding table is shown.
Biological targets
- CB1
- CB2
Binding & functional measurements
Pharmacokinetics
| Bioavailability | Not established for HHC, inhaled cannabinoids are highly variable and oral absorption is low and erratic (extrapolated from THC) |
| Tmax | Not reported |
| Half-life | Not established in humans, expected long and variable (highly lipophilic, fat-stored, THC-like) |
| Vd | Not reported |
| Protein binding | Not reported |
| Metabolism | Hepatic oxidation to hydroxylated metabolites. (9R)- and (9S)-HHC are metabolised and excreted somewhat differently |
| Excretion | Metabolites in urine and faeces. Parent and metabolites detectable in blood, urine and oral fluid |
Toxicology & Safety
Not reported
HHC is intoxicating and impairing much like THC: it slows coordination and reaction time (impairing driving) and can cause anxiety, panic, rapid heart rate and nausea, and, as with high-potency THC, acute psychosis in susceptible people, which has been documented in HHC users. The larger, distinct hazard is that HHC is an unregulated product: vapes, gummies and other goods contain variable, often undisclosed amounts of an epimer mixture of unknown potency, may carry reaction by-products, residual hydrogenation catalysts (metals) or solvents, and are sometimes mislabelled or adulterated. Long-term safety data are essentially absent. Like THC it can produce tolerance and, with heavy regular use, dependence. Avoid driving or operating machinery, and note that combining it with alcohol or other depressants worsens impairment.[5][2]
Legal Status
US: Not scheduled (contested). UK: Class B. DE: Controlled (NpSG)
Interactions & Contraindications
Drug interactions
Contraindications
No interactions or contraindications listed.
Usage & Context
- Sold since around 2021–2022 as a semi-synthetic 'legal high' cannabis substitute, in vapes, e-liquids, edibles (gummies), infused flower and hash, marketed to exploit gaps in cannabis law.
- Used recreationally for cannabis-like effects, and sometimes in the hope of a THC-like high that evades standard THC drug tests, though HHC and its metabolites are increasingly detectable.
- Its rapid spread across Europe and beyond made it one of the most prominent semi-synthetic cannabinoids monitored by drug agencies, prompting a wave of national bans.
Sources & Evidence
- PubChem: Hexahydrocannabinol (CID 16050328) — identifiers & computed properties
- EMCDDA/EUDA: Hexahydrocannabinol (HHC) and related substances — EU Early Warning System technical report (2023)
- Christie R, Conlon R, Néfau T, et al. (2026). Semi-synthetic cannabinoids: Recent developments, analytical challenges and strategic responses. Forensic Sci Int 381:112823.
PMID 41637948 · doi:10.1016/j.forsciint.2026.112823
- Lucuta L, Schwarz L, Liut J, et al. (2025). Inhalation and oral administration of HHC products - Quantification of (9R)-, (9S)-Hexahydrocannabinol and metabolites in plasma and detectability in on-site drug tests for urine and oral fluid. Forensic Sci Int 370:112437.
PMID 40168830 · doi:10.1016/j.forsciint.2025.112437
- O'Mahony B, Lanigan S, Lally N, et al. (2025). Novel substance, same old problems: admissions of psychosis precipitated by hexahydrocannabinol, a widely available semi-synthetic cannabinoid. BJPsych Bull 50:1-6.
PMID 40637199 · doi:10.1192/bjb.2025.85
- Durydivka O, Florián O, Palivec P, et al. (2026). Side-Chain Homologs of Δ(9)-THC, Δ(8)-THC, and HHC Reveal Pathway Bias at CB1R and CB2R Cannabinoid Receptors. Mol Neurobiol 63.
PMID 42625116 · doi:10.1007/s12035-026-06145-8
- PsychonautWiki: HHC — effects, dosage & duration CC BY-SA 4.0
- NpSG — Neue-psychoaktive-Stoffe-Gesetz (Germany). HHC added to the Anlage in 2024
- Wikipedia: Hexahydrocannabinol (chemistry, pharmacology & legal status) CC BY-SA 4.0
- PubChem computed properties (CID 16050328)